Two new transnational calls for proposals in the field of health research, implemented as part of the European PerMed and ERA4Health partnerships, are now open. The PerMed partnership call will focus on cell and gene therapy in personalized medicine approaches. The ERA4Health call aims to support pragmatic, randomized controlled, international, researcher-initiated Phase III clinical intervention studies. The deadline for submitting short proposals for both calls is in January 2027.
Funding for Czech participants is provided by the Ministry of Health through the Czech Health Research Agency. A national budget allocation of 500,000 EUR has been set aside for each call, with a maximum grant amount of 250,000 EUR per project. The project duration for Czech applicants is 36 months.
PerMed – Cell and Gene Therapy for Personalized Medicine (CGT4PM2027)
This call supports international research projects focused on the development and validation of innovative cell and gene therapy approaches in personalized medicine. Projects may address any area of human disease.
Supported approaches include (at least one of the following approaches must be used):
- somatic cell therapy;
- gene therapy;
- combined cell and gene therapy;
- new biological products, such as mRNA, nucleic acid-based technologies, or extracellular vesicles used as gene therapy vectors.
The project consortium must include at least three independent partners from three different eligible EU or associated countries. Typically, it may have a maximum of six partners, although the call rules allow for its expansion under specified conditions. It is mandatory to include at least one early-career researcher (Early-Career Researcher) as the principal investigator (PI).
Deadlines:
- Pre-proposals: January 20, 2027, 2:00 p.m. CET
- Full proposals: May 25, 2027, 2:00 p.m. CEST
- Information webinar: December 3, 2026, 3:00 p.m.–5:00 p.m. CET – REGISTRATION
Detailed information, terms of participation, and documentation: PerMed CGT4PM2027 – AZV ČR.
ERA4Health – Multi-national Investigator-Initiated Clinical Studies (IICS4all 2027)
This call supports international, researcher-initiated, pragmatic, randomized controlled Phase III clinical trials focused on cardiovascular, metabolic, autoimmune, and non-communicable respiratory diseases.
Two types of studies are supported:
- comparative-effectiveness studies of existing healthcare interventions;
- studies of new uses for already approved drugs whose patent protection has expired (drug repurposing).
Studies must focus on at least one or a combination of the following areas:
- cardiovascular diseases;
- metabolic disorders;
- autoimmune diseases;
- non-communicable respiratory diseases.
Emphasis is also placed on the involvement of diverse patient groups and an appropriate clinical trial design.
The consortium must include eligible partners from at least three and no more than five participating countries, with at least two partners coming from two different EU Member States or countries associated with the Horizon Europe program. Under certain conditions, the number of countries may be increased to six if Slovakia participates.
Deadlines:
- Pre-proposals: January 14, 2027, 12:00 p.m. CET
- Full proposals: June 14, 2027, 12:00 p.m. CEST
- Information webinar: November 10, 2026, 2:30–4:30 p.m. CET – REGISTRATION
Detailed information, terms of participation, and documentation: ERA4Health IICS4all 2027 – AZV Czech Republic.
The contact person at AZV ČR for both calls is Mgr. Monika Kocmanová (monika.kocmanova@azvcr.cz, tel. 778 973 186). Questions can also be sent to partnerstvi@azvcr.cz.
Terms of Participation and Information from the UP
Projects are governed by common transnational rules as well as national conditions set by the Ministry of Health (MZd)/AZV of the Czech Republic. Czech applicants must submit the required affidavits and the budget table from the AZV of the Czech Republic. The affidavits will be available upon request at ludmila.hrabakova@upol.cz in the second half of November 2026.
Please send project proposals, including the relevant cover sheet (faculty approval), to the following email address: ludmila.hrabakova@upol.cz well in advance of the deadline for submitting the application and related attachments, no later than:
- PerMed – by 12:00 p.m. on January 19, 2027;
- ERA4Health – by 12:00 p.m. on January 13, 2027;
If you are interested in a consultation or support with preparing and submitting a project application, please contact Project Services at Palacký University in Olomouc. We will be happy to provide you with methodological and administrative support.
The following person is responsible for matters related to the AZV ČR / MZČR: Mgr. Pavla Tresterová
pavla.tresterova@upol.cz
58 563 1419 | 774 709 087
Source: AZV ČR (PerMed), (ERA4Health)